Drug Trial Radar · NCT06828588
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Dec 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 14, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.
Conditions
- Locally Advanced Cancer
- Metastatic Cancer
- HER2
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- HER 2 Low-expressing Breast Cancer
Interventions
[68Ga]Ga-ABY-025Drug
Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine safety of [68Ga]Ga-ABY-025 PET by assessing for adverse events following the injection and PET imaging.Time frame: up to 21± 14 days from second administration of [68Ga]Ga-ABY-025. Assessments will be performed as part of the routine standard of care for patients undergoing HER2-targeted anti-cancer treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.